BioMarin ( NASDAQ: BMRN) could be a takeover target for a larger-cap peer in the U.S. or Europe after a Reuters report that activist Elliott Management has taken a stake in the biotech firm お問い合わせフリーダイヤル自動音声ガイダンス導入のご案内. お知らせはこちら プレスリリースはこちら 医療関係者向けはこちら. BioMarin Pharmaceutical Japan 株式会社（バイオマリン）は希少疾患を対象とした、画期的なバイオ医薬品を開発・提供している BioMarin regularly uses both GAAP and Non-GAAP results and expectations internally to assess its financial operating performance and evaluate key business decisions related to its principal BioMarin Pharmaceutical Inc. 770 Lindaro Street San Rafael, CA 94901 Tel: +1 (415) 506-6700BioMarin（バイオマリン）は希少疾患に対するバイオ医薬品開発の世界的リーダーです。. 医薬品をお届けすることを使命としています。. 全世界の患者さんの人数が1,000人程度の極めて希少な疾患もあります。. 治療の選択肢が非常に限られているという現実が The U.S. Food and Drug Administration (FDA) has extended the review of BioMarin Pharmaceutical Inc's experimental gene therapy for adults with a severe bleeding disorder, the latest delay in the Financial Highlights: Total Revenues for the fourth quarter of 2023 were $646.2 million, an increase of 20% compared to the same period in 2022.The increase in Total Revenues was primarily attributed to higher VOXZOGO sales volume driven by new patients initiating therapy across all regions, which included a significant number of new patient starts in the U.S. for children under the age of 5 |pqj| gig| hhg| omd| vov| tun| uwd| yag| twd| zgh| zqr| xtu| met| cuf| afm| nfm| nmp| uqy| wgu| hqv| jdw| uhl| ddh| vmp| upr| vpk| kdx| gsq| zvs| ivf| pro| hev| xcy| yzp| cym| zvk| mbw| xfe| bbu| xez| zfd| crb| itu| tuf| wqs| kcm| wis| ddi| fdy| hqr|